1235469-00-7

Basic information

• Product Name: 1-Methylindazole-5-boroni...
• Synonyms: 1-Methylindazole-5-boroni...;1-Methyl-1H-indazol-5-ylboronic acid pinacol ester;1H-Indazole, 1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole;1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
• CAS NO: 1235469-00-7
• Molecular Formula: C₁₄H₁₉BN₂O₂
• Molecular Weight: 258.12386
• Product Categories: 6
• Mol File: 1235469-00-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 385.0±15.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.51±0.30(Predicted)
• CAS DataBase Reference: 1-Methylindazole-5-boroni...(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methylindazole-5-boroni...(1235469-00-7)
• EPA Substance Registry System: 1-Methylindazole-5-boroni...(1235469-00-7)

Safety Data

• Hazardous Substances Data: 1235469-00-7(Hazardous Substances Data)

Usage

General Description

1-Methylindazole-5-boronic acid is a chemical compound used in organic synthesis and pharmaceutical research. It is a boronic acid derivative of 1-methylindazole, which is a heterocyclic compound containing an indole ring. Boronic acids are important reagents in organic chemistry due to their ability to form stable covalent bonds with diols and other nucleophiles. 1-Methylindazole-5-boronic acid is commonly used as a building block in the synthesis of biologically active compounds, such as pharmaceutical drugs and agrochemicals. 1-Methylindazole-5-boroni... has shown potential in the development of new drugs for the treatment of various diseases and conditions.

Upstream product

• 53857-57-1 5-bromo-1H-indazole 
• 465529-57-1 5-bromo-1-methyl-1H-indazole 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1607837-31-9 8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 
• 1229207-08-2 N-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 

Relevant articles and documents

Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation

CDK8 is deregulated in multiple types of human cancer and is viewed as a therapeutic target for the treatment of the disease. Accordingly, the search for small-molecule inhibitors of CDK8 is being intensified. Capitalising on our initial discovery of AU1-100, a potent CDK8 inhibitor yet with a limited degree of kinase selectivity, a structure-based optimisation was carried out, with a series of new multi-substituted pyridines rationally designed, chemically prepared and biologically evaluated. Such endeavour has culminated in the identification of 42, a more potent CDK8 inhibitor with superior kinomic selectivity and oral bioavailability. The mechanism underlying the anti-proliferative effect of 42 on MV4-11 cells was studied, revealing that the compound arrested the G1 cell cycle and triggered apoptosis. The low risk of hepato- and cardio-toxicity of 42 was estimated. These findings merit further investigation of 42 as a targeted cancer therapeutic.

SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS

The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, L, m, p and W are as defined in the specification.